SCCM Resource Library-Moving Away From Catecholamine Monotherapy in Shock

Moving Away From Catecholamine Monotherapy in Shock

Video Transcription

Video Summary

The speaker discusses strategies for managing septic shock, emphasizing the limitations of catecholamine monotherapy and suggesting alternative approaches with vasopressors like vasopressin and angiotensin II. He highlights research showing that high-dose catecholamines are associated with increased mortality and morbidity. The speaker advocates for early multimodal vasopressor therapy, supported by targeted biomarkers, and highlights the importance of timely intervention. The discussion includes challenges with traditional methods and the potential benefits of integrating beta blockers and alternative vasopressors to improve patient outcomes in septic shock.

Asset Caption

One-Hour Concurrent Session | Flipping the Script: Beta-Blockers in Shock

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

septic shock

vasopressors

catecholamines

multimodal therapy

biomarkers

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.